The Retina Partners is proud to participate in clinical research evaluating innovative treatments for a variety of retinal diseases. Each clinical trial follows a carefully designed protocol with specific eligibility requirements to help ensure participant safety and the integrity of the research. Our experienced research team will review your medical history, discuss studies for which you may qualify, explain what participation involves, and answer any questions you may have so you can make an informed decision. Participation in a clinical trial is completely voluntary. Choosing to participate or deciding not to participate will not affect the quality of care you receive at The Retina Partners. If you enroll in a study, you may withdraw at any time for any reason. By participating in research, our patients play an important role in helping develop the next generation of therapies that may improve vision and quality of life for future patients.
Interested in Participating? If you're interested in learning more about our current clinical trials, schedule an appointment with one of our retina specialists. If you may be eligible for a study, your physician can refer you to our dedicated Research Department for further evaluation.
Below is a list of our studies that are currently enrolling new patients. Click on the name of the study to be directed to each study-specific page on clinicaltrials.gov
Achieve : Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Torrontes : A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD) (MK-8748-003)
Gallop : A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy
Sanofi : A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Helios : A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy (HELIOS-3)
Naavigate : Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Welcome to the Institutional Biosafety Committee (IBC) Meeting Minutes archive. The IBC is responsible for reviewing research involving recombinant or synthetic nucleic acid molecules and other biohazardous materials to ensure compliance with institutional, federal, and local biosafety regulations.
Below you will find a link to summaries of our committee meetings, including key decisions, protocol reviews, and updates on biosafety practices. These minutes are provided to promote transparency and support our commitment to safe and ethical research.